Related Experiment Video
Updated: Mar 29, 2026
Pseudomonas aeruginosa Induced Lung Injury Model
Published on: October 29, 2014
Monosodium Glutamate Inhibits Pseudomonas aeruginosa-Induced Acute Lung Injury by Targeting the Type III Secretion
Jing Xu1,2, Weiwei Wang1,2, Yaxin Zhou1,2
1Key Laboratory of New Animal Drug Project of Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development of the Ministry of Agriculture and Rural Affairs, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China.
Abstract:
The opportunistic pathogen Pseudomonas aeruginosa poses a serious threat to immunocompromised patients. Monosodium glutamate (MSG), a widely used flavor enhancer, has been reported to possess anti-inflammatory and antioxidant properties. However, its therapeutic potential and mechanism against Pseudomonas aeruginosa (P. aeruginosa) infection have remained unexplored. This study systematically elucidated the protective effects and molecular mechanisms of MSG against P. aeruginosa-induced acute lung injury (ALI). In a murine pneumonia model, MSG administration effectively alleviated lung pathological damage, edema, and inflammatory responses. Mechanistically, MSG exerted protection through a multifaceted strategy, including direct suppression of bacterial virulence via binding to PopB of T3SS inhibition of the TLR4/MyD88/MAPK-driven inflammatory cascade and pro-inflammatory cytokine production, enhancement of endogenous antioxidant defense (SOD, CAT), and reshaping of pulmonary macrophages from the M1 to M2 phenotype. Notably, the anti-virulence effect of MSG, achieved by binding to PopB (KD = 3.52 × 10-6 M), presented a distinct advantage over traditional antimicrobials by potentially mitigating resistance development. Collectively, these findings indicated that MSG can alleviate ALI caused by P. aeruginosa infection.
Insights
Monosodium glutamate (MSG) alleviates lung injury from Pseudomonas aeruginosa infection by reducing inflammation and bacterial virulence. This flavor enhancer offers a novel therapeutic strategy against bacterial lung damage.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Pseudomonas aeruginosa is an opportunistic pathogen causing severe infections, particularly in immunocompromised individuals.
- Monosodium glutamate (MSG) exhibits anti-inflammatory and antioxidant properties, but its therapeutic role in P. aeruginosa infections is unknown.
Purpose of the Study:
- To investigate the protective effects and molecular mechanisms of MSG against P. aeruginosa-induced acute lung injury (ALI).
Main Methods:
- A murine pneumonia model was used to assess MSG's efficacy.
- Mechanistic studies involved analyzing bacterial virulence, inflammatory pathways (TLR4/MyD88/MAPK), antioxidant enzyme activity (SOD, CAT), and macrophage polarization (M1/M2).
- MSG's binding affinity to PopB of P. aeruginosa T3SS was determined.
Main Results:
- MSG administration reduced lung pathological damage, edema, and inflammation in the murine model.
- MSG directly suppressed bacterial virulence by binding to PopB (KD = 3.52 × 10-6 M), inhibiting the T3SS.
- MSG modulated the TLR4/MyD88/MAPK pathway, boosted antioxidant defenses (SOD, CAT), and shifted pulmonary macrophages to an M2 phenotype.
Conclusions:
- MSG demonstrates significant protective effects against P. aeruginosa-induced ALI.
- MSG's multifaceted mechanism includes direct anti-virulence activity, anti-inflammatory effects, enhanced antioxidant capacity, and immunomodulation.
- MSG represents a promising therapeutic agent for P. aeruginosa infections, potentially overcoming antimicrobial resistance issues.
Related Concept Videos
01:28Gene Regulation in Microbial Communities: Quorum Sensing
01:14Atypical Pneumonia